Rain Therapeutics Inc. (RAIN): Price and Financial Metrics
RAIN Price/Volume Stats
| Current price | $1.21 | 52-week high | $11.32 |
| Prev. close | $1.23 | 52-week low | $0.82 |
| Day low | $1.21 | Volume | 3,706,000 |
| Day high | $1.27 | Avg. volume | 550,818 |
| 50-day MA | $1.16 | Dividend yield | N/A |
| 200-day MA | $2.14 | Market Cap | 44.01M |
RAIN Stock Price Chart Interactive Chart >
Rain Therapeutics Inc. (RAIN) Company Bio
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
RAIN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 13.08% |
| 3-year | -91.84% |
| 5-year | N/A |
| YTD | 0.83% |
| 2023 | -85.00% |
| 2022 | -37.89% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...